-

Faeth Therapeutics to Participate in Upcoming September Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:

  • Wells Fargo 21st Annual Healthcare Conference
    Tuesday, September 8, 2026
    1x1 investor meetings
    Boston, MA

  • Citi Biopharma Back to School Summit
    Wednesday, September 9, 2026
    Fireside chat at 10:00 a.m. ET
    New York, NY

  • Cantor Global Healthcare Conference 2026
    Thursday, September 10, 2026
    Fireside chat at 8:35 a.m. ET
    New York, NY
    Webcast Link

  • Morgan Stanley 24th Annual Global Healthcare Conference
    Monday, September 14 & Wednesday, September 16, 2026
    Fireside chat at 9:15 a.m. EDT on Wednesday
    New York, NY
    Webcast Link

  • Baird Global Healthcare Conference
    Tuesday, September 15, 2026
    Fireside chat at 10:15 a.m. ET
    New York, NY

  • H.C. Wainwright 28th Annual Global Investment Conference
    Wednesday, September 16, 2026
    Fireside chat at 10:30 a.m. ET
    New York, NY

  • Deutsche Bank 2026 Healthcare Summit
    Thursday, September 17, 2026
    1x1 investor meetings
    New York, NY

Live webcasts of the Cantor and Morgan Stanley fireside chats can be accessed via the Events and Presentations section of the Faeth website at investors.faeththerapeutics.com. Replays will be available for approximately 90 days following the event.

About Faeth Therapeutics

Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.D. For more information, please visit www.faeththerapeutics.com and follow the Company on LinkedIn.

Contacts

Investor Contact:
Matthew Biegler, SVP, Investor Relations
matt@faeththerapeutics.com

Media Contact:
Patrick Schmidt, Consort Partners
faeththerapeutics@consortpartners.com

Industry:

Faeth Therapeutics

NASDAQ:FTH
Release Versions
English

Contacts

Investor Contact:
Matthew Biegler, SVP, Investor Relations
matt@faeththerapeutics.com

Media Contact:
Patrick Schmidt, Consort Partners
faeththerapeutics@consortpartners.com

Social Media Profiles
Faeth Therapeutics on LinkedIn
More News From Faeth Therapeutics

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company’s common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 25, 2026, pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment...

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and serabelisib (PIKTOR) with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and...

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones. Tiwari will lead Faeth’s technical operations organization, overseeing chemistry, manufacturing and controls (CMC), and supply chain activities supporting the company’s PIKTOR clinical development progr...
Back to Newsroom